Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Phase of Trial: Phase II/III
Latest Information Update: 05 May 2017
At a glance
- Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Cyclophosphamide; Docetaxel; Epirubicin; Exemestane; Letrozole; Tamoxifen
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms ADAPT; ADAPT-HR+HER2-
- 07 Jun 2017 Biomarkers information updated
- 25 Sep 2013 New source identified and integrated (German Clinical Trials Register; DRKS00005203).
- 07 Jun 2013 Trial protocol presented at ASCO 2013.